Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

Clin Colorectal Cancer. 2020 Sep;19(3):e71-e72. doi: 10.1016/j.clcc.2020.02.011. Epub 2020 Mar 6.

Authors

Deniz Can Guven¹, Gurkan Guner², Burak Yasin Aktas², Oktay Halit Aktepe², Hakan Taban², Zafer Arik²

Affiliations

¹ Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey. Electronic address: [email protected].
² Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey.

PMID: 32224043
DOI: 10.1016/j.clcc.2020.02.011

No abstract available

Publication types

Letter
Comment

MeSH terms

Chemotherapy, Adjuvant
Colonic Neoplasms* / drug therapy
Humans
Leucovorin / therapeutic use
Oxaliplatin / therapeutic use
Tegafur*

Substances

Oxaliplatin
Tegafur
Leucovorin